TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$110 Million

Keryx Biopharmaceuticals

Follow-on Offering

Lead Manager, January 2015

Operator of a biopharmaceutical company focused on bringing innovative medicines to people with renal disease. The company is focused on the development and commercialization of medicines that provide unique and meaningful advantages to people with renal disease and their healthcare providers.